- Home
- IFRX vs FSEA Comparison
IFRX vs FSEA Comparison
Compare IFRX & FSEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- FSEA
- Stock Information
- Founded
- IFRX 2007
- FSEA 1890
- Country
- IFRX Germany
- FSEA United States
- Employees
- IFRX N/A
- FSEA N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- FSEA Savings Institutions
- Sector
- IFRX Health Care
- FSEA Finance
- Exchange
- IFRX Nasdaq
- FSEA Nasdaq
- Market Cap
- IFRX 53.5M
- FSEA 53.7M
- IPO Year
- IFRX 2017
- FSEA N/A
- Fundamental
- Price
- IFRX $1.14
- FSEA $11.51
- Analyst Decision
- IFRX Strong Buy
- FSEA
- Analyst Count
- IFRX 5
- FSEA 0
- Target Price
- IFRX $7.40
- FSEA N/A
- AVG Volume (30 Days)
- IFRX 1.0M
- FSEA 2.4K
- Earning Date
- IFRX 11-07-2025
- FSEA 11-07-2025
- Dividend Yield
- IFRX N/A
- FSEA N/A
- EPS Growth
- IFRX N/A
- FSEA N/A
- EPS
- IFRX N/A
- FSEA N/A
- Revenue
- IFRX $191,224.00
- FSEA $14,095,000.00
- Revenue This Year
- IFRX N/A
- FSEA N/A
- Revenue Next Year
- IFRX $1,216.24
- FSEA N/A
- P/E Ratio
- IFRX N/A
- FSEA N/A
- Revenue Growth
- IFRX 54.36
- FSEA 30.26
- 52 Week Low
- IFRX $0.71
- FSEA $8.90
- 52 Week High
- IFRX $2.82
- FSEA $11.95
- Technical
- Relative Strength Index (RSI)
- IFRX 45.40
- FSEA 49.45
- Support Level
- IFRX $1.45
- FSEA $11.50
- Resistance Level
- IFRX $1.77
- FSEA $11.62
- Average True Range (ATR)
- IFRX 0.21
- FSEA 0.13
- MACD
- IFRX -0.04
- FSEA -0.01
- Stochastic Oscillator
- IFRX 24.94
- FSEA 15.22
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities, and bank-owned life insurance.